Electron microscopic findings can support multiple etiologies of nephrotoxicity in renal tubules

References

• Herrera GA. The value of ultrastructural evaluation in medical renal diseases. Ultrastruct Pathol. 2019;43(6):225–228. doi:10.1080/01913123.2019.1696575.
   PubMed Web of Science ®Google Scholar
• Beck LH Jr. PLA2R and THSD7A: disparate paths to the same disease? J Am Soc Nephrol. 2017;28(9):2579–2589. doi:10.1681/ASN.2017020178.
   PubMed Web of Science ®Google Scholar
• Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789–796. doi:10.1016/j.kint.2017.11.023.
   PubMed Web of Science ®Google Scholar
• Ronco P, Debiec H. Membranous glomerulopathy: the evolving story. Curr Opin Nephrol Hypertens. 2010;19(3):254–259. doi:10.1097/MNH.0b013e328336eafd.
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach. J Am Soc Nephrol. 2015;26(12):2917–2929. doi:10.1681/ASN.2015020184.
   PubMed Web of Science ®Google Scholar
• Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012;81(5):434–441. doi:10.1038/ki.2011.399.
   PubMed Web of Science ®Google Scholar
• Thurman JM, Nester CM. All things complement. Clin J Am Soc Nephrol. 2016;11(10):1856–1866. doi:10.2215/CJN.01710216.
   PubMed Web of Science ®Google Scholar
• D’Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368–382. doi:10.1053/j.ajkd.2003.10.024.
   PubMed Web of Science ®Google Scholar
• Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164–1172.
   PubMed Web of Science ®Google Scholar
• Neyra JA, Vaidya OU, Hendricks A, Sambandam KK. Collapsing focal segmental glomerulosclerosis resulting from a single dose of zoledronate. Nephron Extra. 2014;4(3):168–174. doi:10.1159/000366450.
   PubMedGoogle Scholar
• Kfoury H, Arafah M. The pathological spectrum associated with the ultrastructural finding of thin glomerular basement membrane: A tertiary medical city experience and review of the literature. Ultrastruct Pathol. 2017;41(1):51–54. doi:10.1080/01913123.2016.1258021.
   PubMed Web of Science ®Google Scholar
• Frasca GM, Onetti-Muda A, Mari F, et al. Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis–a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant. 2005;20(3):545–551. doi:10.1093/ndt/gfh617.
   PubMed Web of Science ®Google Scholar
• Namal RR, Ranathunga PAN, Kularatne SA. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura following hump-nosed pit viper (Genus: hypnale) envenoming in Sri Lanka. Wilderness Environ Med. 2019;30(1):66–78. doi:10.1016/j.wem.2018.10.003.
   PubMed Web of Science ®Google Scholar
• Sethi S, Rajkumar SV, D’Agati VD, Complexity T. Heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol. 2018;29(7):1810–1823. doi:10.1681/ASN.2017121319.
   PubMed Web of Science ®Google Scholar
• Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45–59. doi:10.1038/s41581-018-0077-4.
   PubMed Web of Science ®Google Scholar
• Parasuraman R, Wolforth SC, Wiesend WN, et al. Contribution of polyclonal free light chain deposition to tubular injury. Am J Nephrol. 2013;38(6):465–474. doi:10.1159/000356557.
   PubMed Web of Science ®Google Scholar
• Hayek S, Parasuraman R, Desai HS, et al. Primary cilia metaplasia in renal transplant biopsies with acute tubular injury. Ultrastruct Pathol. 2013;37(3):159–163. doi:10.3109/01913123.2013.768745.
   PubMed Web of Science ®Google Scholar
• Herrera GA. Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis. Arch Pathol Lab Med. 2014;138(10):1365–1380. doi:10.5858/arpa.2013-0493-OA.
   PubMed Web of Science ®Google Scholar
• Bridoux F, Leung N, Hutchison CA, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698–711. doi:10.1038/ki.2014.408.
   PubMed Web of Science ®Google Scholar
• Appel GB. Aminoglycoside nephrotoxicity. Am J Med. 1990;88(3C):16S-20S; discussion 38S-42S. doi:10.1016/0002-9343(90)90082-O.
   PubMed Web of Science ®Google Scholar
• Salim SA, Everitt J, Schwartz A, et al. Aminoglycoside impregnated cement spacer precipitating acute kidney injury requiring hemodialysis. Semin Dial. 2018;31(1):88–93. doi:10.1111/sdi.12639.
   PubMed Web of Science ®Google Scholar
• Luque Y, Louis K, Jouanneau C, et al. Vancomycin-associated cast nephropathy. J Am Soc Nephrol. 2017;28(6):1723–1728. doi:10.1681/ASN.2016080867.
   PubMed Web of Science ®Google Scholar
• Bailly E, Von Tokarski F, Beau-Salinas F, et al. Interstitial nephritis secondary to vedolizumab treatment in Crohn disease and safe rechallenge using steroids: a case report. Am J Kidney Dis. 2018;71(1):142–145. doi:10.1053/j.ajkd.2017.08.008.
   PubMed Web of Science ®Google Scholar
• Zhang PL, Rothblum LI, Han WK, Blasick TM, Potdar S, Bonventre JV. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int. 2008;73:608–614.
   PubMed Web of Science ®Google Scholar
• Yin W, Kumar T, Lai Z, et al. Kidney injury molecule-1, a sensitive and specific marker for identifying acute proximal tubular injury, can be used to predict renal functional recovery in native renal biopsies. Int Urol Nephrol. 2019;51(12):2255–2265. doi:10.1007/s11255-019-02311-1.
   PubMed Web of Science ®Google Scholar
• Cronin RE. Aminoglycoside nephrotoxicity: pathogenesis and prevention. Clin Nephrol. 1979;11:251–256.
   PubMed Web of Science ®Google Scholar
• Jospe-Kaufman M, Siomin L, Fridman M. The relationship between the structure and toxicity of aminoglycoside antibiotics. Bioorg Med Chem Lett. 2020;30(13):127218. doi:10.1016/j.bmcl.2020.127218.
   PubMed Web of Science ®Google Scholar
• Schmitz C, Hilpert J, Jacobsen C, et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem. 2002;277(1):618–622. doi:10.1074/jbc.M109959200.
   PubMed Web of Science ®Google Scholar
• Taber SS, Pasko DA. The epidemiology of drug-induced disorders: the kidney. Expert Opin Drug Saf. 2008;7(6):679–690. doi:10.1517/14740330802410462.
   PubMed Web of Science ®Google Scholar
• Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79(1):33–45. doi:10.1038/ki.2010.337.
   PubMed Web of Science ®Google Scholar
• Chwieralski CE, Welte T, Buhling F. Cathepsin-regulated apoptosis. Apoptosis. 2006;11:143–149.
   PubMed Web of Science ®Google Scholar
• Golstein P, Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci. 2007;32(1):37–43. doi:10.1016/j.tibs.2006.11.001.
   PubMed Web of Science ®Google Scholar
• Gudmundsson GH, Jensen LJ. Vancomycin and nephrotoxicity. Lancet. 1989;1(8638):625. doi:10.1016/S0140-6736(89)91664-4.
   PubMedGoogle Scholar
• Gupta A, Biyani M, Khaira A. Vancomycin nephrotoxicity: myths and facts. Neth J Med. 2011;69:379–383.
   PubMed Web of Science ®Google Scholar
• Gelfand MS, Cleveland KO. Vancomycin-induced nephrotoxicity. Antimicrob Agents Chemother. 2013;57(5):2435. doi:10.1128/AAC.00253-13.
   PubMed Web of Science ®Google Scholar
• Tantranon N, Luque Y, Barrios R, Gaber L, Truong L. Vancomycin-related nephropathy: comprehensive evaluation of 36 biopsies. Modern Pathol. 2019;32:1615.
   Web of Science ®Google Scholar
• Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAbs. 2013;5(6):842–850. doi:10.4161/mabs.26392.
   PubMed Web of Science ®Google Scholar
• Pijls PA, Gilissen LP. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects. Dig Liver Dis. 2016;48(11):1391–1393. doi:10.1016/j.dld.2016.08.122.
   PubMedGoogle Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–27 e3.
   PubMed Web of Science ®Google Scholar